# A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin

> **NCT01713530** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 274 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** insulin degludec/insulin aspart
- **DRUG:** insulin degludec
- **DRUG:** insulin aspart

## Key facts

- **NCT ID:** NCT01713530
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-21
- **Primary completion:** 2014-01-09
- **Final completion:** 2014-01-09
- **Target enrollment:** 274 (ACTUAL)
- **Last updated:** 2018-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01713530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01713530, "A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01713530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*